Boulegeris Investments Inc. raised its position in shares of Allergan PLC. (NYSE:AGN) by 6.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,605 shares of the company’s stock after buying an additional 2,125 shares during the period. Allergan PLC. comprises about 4.6% of Boulegeris Investments Inc.’s investment portfolio, making the stock its 6th biggest holding. Boulegeris Investments Inc.’s holdings in Allergan PLC. were worth $8,169,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in AGN. Waldron LP purchased a new stake in Allergan PLC. during the 1st quarter valued at $348,000. Adell Harriman & Carpenter Inc. boosted its position in Allergan PLC. by 52.9% during the 1st quarter. Adell Harriman & Carpenter Inc. now owns 23,310 shares of the company’s stock valued at $5,569,000 after buying an additional 8,069 shares during the period. Grimes & Company Inc. boosted its position in Allergan PLC. by 14.5% during the 1st quarter. Grimes & Company Inc. now owns 14,224 shares of the company’s stock valued at $3,399,000 after buying an additional 1,799 shares during the period. Pillar Pacific Capital Management LLC boosted its position in Allergan PLC. by 11.0% during the 1st quarter. Pillar Pacific Capital Management LLC now owns 18,070 shares of the company’s stock valued at $4,318,000 after buying an additional 1,797 shares during the period. Finally, Chicago Equity Partners LLC boosted its position in Allergan PLC. by 1,614.8% during the 1st quarter. Chicago Equity Partners LLC now owns 26,150 shares of the company’s stock valued at $6,248,000 after buying an additional 24,625 shares during the period. 82.02% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Boulegeris Investments Inc. Purchases 2,125 Shares of Allergan PLC. (AGN)” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.chaffeybreeze.com/2017/09/19/boulegeris-investments-inc-purchases-2125-shares-of-allergan-plc-agn.html.
Allergan PLC. (NYSE AGN) opened at 221.54 on Tuesday. The company has a 50 day moving average of $230.85 and a 200 day moving average of $236.29. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company has a market capitalization of $74.06 billion, a price-to-earnings ratio of 6.75 and a beta of 1.18.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $3.35 earnings per share. On average, equities analysts forecast that Allergan PLC. will post $16.25 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were issued a $0.70 dividend. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.26%. Allergan PLC.’s dividend payout ratio is presently 9.95%.
Several equities research analysts have weighed in on AGN shares. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, June 8th. Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Mizuho dropped their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research report on Friday, June 9th. Royal Bank Of Canada reissued a “buy” rating and set a $285.00 price target on shares of Allergan PLC. in a research report on Wednesday, September 6th. Finally, Cantor Fitzgerald started coverage on shares of Allergan PLC. in a research report on Friday, June 16th. They set a “neutral” rating and a $231.00 price target for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company’s stock. Allergan PLC. currently has a consensus rating of “Buy” and a consensus price target of $274.69.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.